Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Dry skin, Erythema, Pain, Pruritus, SARS-CoV-2 test
Clinical narrative: After receiving both doses of pfizer my skin has been very reactive.; My usual dry spot sometimes will turn red and raised but not itchy. A first time symptom Ive had is a break out on my face that is raised and red. Itchy at first, but at its peak is extremely painful, raised, red and rough to the touch.; My usual dry spot sometimes will turn red and raised but not itchy. A first time symptom Ive had is a break out on my face that is raised and red. Itchy at first, but at its peak is extremely painful, raised, red and rough to the touch.; My usual dry spot sometimes will turn red and raised but not itchy. A first time symptom Ive had is a break out on my face that is raised and red. Itchy at first, but at its peak is extremely painful, raised, red and rough to the touch.; A first time symptom Ive had is a break out on my face that is raised and red. Itchy at first, but at its peak is extremely painful, raised, red and rough to the touch. When it starts to go away my skin will flake away.; A first time symptom Ive had is a break out on my face that is raised and red. Itchy at first, but at its peak is extremely painful, raised, red and rough to the touch. When it starts to go away my skin will flake away.; A first time symptom Ive had is a break out on my face that is raised and red. Itchy at first, but at its peak is extremely painful, raised, red and rough to the touch. When it starts to go away my skin will flake away.; This is a spontaneous report from a contactable nurse, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EK9231) via an unspecified route of administration in the left arm on an 21Feb2021 at 13:00 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety and dry skin. Concomitant medications taken within two weeks prior to vaccination included phentermine (MANUFACTURER UNKNOWN). The patient previously took Macrobid and Bisacodyl and experienced drug allergy to Macrobid and Bisacodyl. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an 17Jan2021 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient has had dry parts of her body leading up to her vaccinations. On 21Mar2021 at 12:00 after receiving both doses of pfizer the patients skin had been very reactive. Her usual dry spot sometimes would turn red and raised but not itchy, this didn't happen before. Other times her dry spots would be extremely itchy. A first time symptom the patient had was a break out on her face that was raised and red. Itchy at first, but at its peak was extremely painful, raised, red and rough to the touch. When it started to go away her skin would flake away on an unknown date in 2021. It lasted for a few days and then went away. The patient would be going to see a dermatologist soon as the symptoms were not subsiding. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether therapeutic measures were taken as a result of the events. On 01Mar2021, the patient underwent COVID- 19 test via nasal swab and the result was negative. The clinical outcome of the events skin had been very reactive, usual dry spot sometimes would turn red and raised but not itchy, this didn't happen before; other times dry spots would be extremely itchy, a break out on her face that was raised and red, itchy at first, but at its peak was extremely painful, raised, red and rough to the touch; when it started to go away her skin would flake away was not resolved at the time of report.   No follow-up attempts are needed. No further information is expected.